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In two groups of volunteers pharmacological parameters 
of the antihypotensive drug midodrine have been inves-
tigated. The first group of 12 male healthy volunteers 
received 2.5 mg midodrine hydrochloride intravenous-
ly, as drinking solution or as tablet according to a ran-
domized cross-over design. Plasma and urine samples 
were analyzed for midodrine and its main metabolite 
ST 1059 by high-performance liquid chromatography. 
The mean maximum concentration in plasma for mido-
drine was 10 ng/ml 20-30 min after oral administration, 
for ST 1059 5 ng/ml after 1 h. Midodrine was eliminat-
ed with a terminal half-life of 0,5 h, ST 1059 with a half-
life of 3 hrs. The mean area under the plasma-level vs. 
time curve (AUC) of ST 1059 after administration of 2.5 
mg midodrine i.v. was 28.7 ngXh/ml, and similar for 
the other formulations which are considered to be bi-
oequivalent. In a second group of 15 volunteers with 
postural hypotension midodrine (M) as a-sympatho-
mimetic drug and oxilofrine (O) as ^-sympathomimetic 
drug was given i.v. in a randomized double blind study 
against placebo (P). Blood pressure (BP), heart rate (HR) 
and circulating catecholamines (CA) were determined be-
fore and after injections of the drugs as well as before 
and during 10 min of tilting. Echocardiographic para-
meters were obtained at rest before and after the ad-
ministration of the drugs. Blood pressure remained un-
changed at rest and during orthostasis after all agents 
injected. After oral administration of midodrine heart 
rate was decreased and systolic blood pressure increased 
significantly and dose-dependently. M lowered circulat-
ing noradrenaline. Echocardiographic parameters were 
changed after administration of M (increase in end-di-
astolic volume index and SVI) and O (increase in SVI, 
E F and cardiac index). The observed changes in sym-
pathetic and cardiovascular parameters are in agree-
ment with the sympathomimetic actions of the drugs 
investigated and allow a differential therapeutic clas-
sification: M is suitable for patients with sympathoton-
ic orthostatic reaction; O should be recommended for 
patients with asympathotonic orthostatic reaction. 
[Int Ang io l 1993; 12:119-124]. 
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In the past decade among the sympathomimet-
ic drugs used for therapeutic intervention in or-
thostatic hypotension, midodrine (Fig. 1) as a po-
tent and selective peripherally acting as a-
receptor agonist hast been established. 1 Phar-
macological properties, therapeutic trials, ad-
verse effects, dosage, and administration were 
reviewed recently. 2 
The aim of this paper is to summarize the in-
vestigations from our laboratory concerning 
pharmacodynamic properties and pharmacoki-
netic parameters of midodrine in young patients 
with orthostatic dysregulation and in healthy 
volunteers, respectively. 
Patients volunteers and methods 
Study 1 
Haemodynamic effects. The study was per-
formed in 15 young patients (i.v. administration) 
This paper was presented at the X V I Wor ld Congress of 
the International Union of Aneiology (Paris, September 13-
18, 1992). 
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Fig. 1.—Conversion of midodrine to its active metabolite, 
deglymidodrine, via enzymatic hydrolysis in vivo. 
or five volunteers for oral administration (Ta-
ble I). The following parameters should be ful-
filled twice by the volunteers prior to the study: 
1. Systolic blood pressure after 30 min su-
pine < 130 mmHg. 
2. Decrease in systolic blood pressure dur-
ing passive Orthostase after til t ing with feet lo-
wered at 90°: >15 mmHg (this method for in-
ducing orthostatic hypotension is described by 
de Marees et ai, 1975); when collapse occurred, 
this requirement was regarded as fulfilled. 
3. Pressure-dependent venous capacity of one 
leg at 70 mmHg pressure: 4.5-5.5 ml/100 ml soft 
tissue. 
In a double blind, intraindividual and ran-
domized order, the i.v. study was performed in 
volunteers receiving acute aequieffective doses, 
aequieffective with respect to the blood pressure, 
5 mg midodrine* and 20 mg oxilofrine** in-
travenously (i.v.) within 2 minutes versus place-
bo. Between the drug administration an inter-
val of 7 days was maintained. Haemodynamic 
*Gutron® . 
**Carnigen ( 
T A B L E I.—Data of patients. 
i.v. ad mi nisi rati on Oral uealment 
Number of patients 15 5 
— male 5 5 
— female 10 — 
Age (years) 22.4 ±3 .1 37 .6±11 .2 
Weight (kg) 60 .9±8 .5 71 .6±8 .2 
Height (cm) 171.9±6.6 179.2±9.7 
The values are given as mean ±standard deviation. 
measurements were performed in the morning 
in a room with a temperature of 24°C after at 
least 12 hours abstinence from alcohol and 
caffeine. Increasing doses of midodrine were ad-
ministered orally in a controlled open study: 2.5 
mg, followed by 7.5 mg and 15 mg. 
Blood pressure and heart rate.—Prior to inves-
tigation, an indwelling catheter was introduced 
into an antecubital vein of each volunteer. Af-
ter 30 min supine, samples of 5 ml blood were 
taken for assay of circulating catecholamines 
(noradrenaline and adrenaline after i.v. injection 
of the drugs). Pressure-dependent venous capac-
ity and resting values for blood pressure 
(RR = combined Riva Rocci/Korotkoff method) 
and heart rate (via ECG) were determined. 
Resting blood pressure refers to the value taken 
immediately before til t ing. 
Resting blood pressure after injection of the 
drugs investigated was obtained 30 min after i.v. 
administration, immediately before tilting. Dur-
ing the subsequent 10 minutes of passive Or-
thostase (tilting table, feet lowered at 90°; as 
described by de Marees et al.} 1975), blood pres-
sure and heart rate were taken at 1-minute in-
tervals and blood samples for plasma catechola-
mine assay were taken after 1st, 2nd, 5th, and 
10th minute. In the study with oral administra-
tion of midodrine heart rate and blood pressure 
were determined after each dose in 10-minute 
intervals. 
Echocardiography.—Cardiac parameters were 
estimated after i.v. injection of the drugs by 2-
D-echocardiographic sonography (Sonotron Di-
asonic L V 3400 R) and evaluated by Cardio 80 
(Fa. Kontron; Chapman's biplane method). 
ECG-triggered end-diastolic and end-systolic 
T A B L E II.—Initial values of cardiovascular data (blood pressure and heart rate). 
Before medical ion Afler medical ions 
SBP DBP HR SBP DBP HR 
(mmHg) (mmHg) (b min) (mmHg) (mmHg) (b min) 
Placebo 113.0±6.6 70 .6±5 .0 74 .9±12 .8 112.6±7.4 7 3 . 9 ± 7 . 0 70.9 ± 11.6* 
Midodr ine 111.5 ±9 .3 71 .1±7 .0 74 .7±11 .2 112.9±9.3 7 3 . 9 ± 8 . 5 64 .3± 10.5** 
Oxilofrine 1 11.9±7.7 70.5 ±8 .1 73.3 ± 12.4 116.6± 10.1 72.3 ±10 .1 73 .9±12 .0 
Abbreviations: SBP systolic blood pressure, DBP = diastolic blood pressure, HR — heart rate. 
The values are given as mean ± standard deviation. 
Significance: * - p<0.05. **-p<0.001. 
T A B L E III.—Route of application. 
Route of application 
Parameter Oi -al 
I.V. 
Solution Tablet 
t-max (h) — 1.1 ±0 .5 1.1 ± 0 . 5 
C m a x ( n g / m l ) — 4.6 ± 1 . 0 5 .0±1 .6 
tlA (h) 3.1 ±0 .5 3 .0±0 .4 3 .0±0 .5 
A U C (ngxh/ml) 2 8 . 7 ± 6 . 6 25 .7±6 .6 25 .6±6 .2 
CI (ml/min) 1200 ± 2 2 9 1 3 9 2 ± 2 7 8 1378±319 
V( ! ) 3 1 9 ± 6 1 3 5 5 ± 8 1 3 5 3 ± 8 0 
Uo-24 h (% der Dosis) 39 .8±3 .8 34 .4±2 .6 34 .4±4 .5 
k = distribution volume. 
silhouettes of the heart were determined after 
freezing, and stroke volume, ejection fraction 
and cardiac output were calculated and depict-
ed as the indices (ml/m2). 
The volunteers were then given the scheduled 
drug and the sequence of investigations describ-
ed above was repeated 30 min later. 
Plasma catecholamines.—To determine the 
plasma catecholamine concentrations, 5 ml blood 
were taken through the catheter and placed in 
ice cold PP tubes containing EGTA/glutathione 
ul . Immediately after mixing, the blood samples 
were centrifuged for 10 min at 4°C and 5000 X g , 
and the plasma was stored at - 7 0 ° C unti l as-
say. Noradrenaline and adrenaline were deter-
mined by high pressure l iquid chromatography 
(HPLC) and electrochemical detection. 
Study 2 
Pharmacokinetic parameters.—Volunteers, 
methods and material has been described exten-
sively elsewhere. 3 
Results 
Study 1 
Haemodynamics and circulating (Table II) 
noradrenaline as biochemical index of sym-
pathetic tone. 
Blood pressure and heart rate.—The ini t ia l 
values for blood pressure and heart rate were 
comparable in the different groups, and resting 
Fig. 2.—Blood pressure (BP) using passive orthostasis betö-
re (open columns) and after (hatched columns) i.v. injection 
of the various antihypertensive agents. Abbreviations: PCB = 
placebo, M D D = midodrine, O X F = oxilofrine. 
Fig. 3.—Blood pressure (BP) and heart rate (HR) during oral 
administration of midodrine. After increasing doses B P and 
H R are depicted as percent of basic values from 5 volunteers. 
Before treatment = 100% ( m e a n ± S E M , N = 5). Significance: 
* = p<0.01. 
blood pressure was not influenced by adminis-
tration of the different antihypotensive agents 
and placebo. 
However, the resting heart rate decreased sig-
nificantly by 10.5 and 11.6 beats/min, respective-
ly, after injection of midodrine and placebo. Ox-
ilofrine did not change the heart rate. 
Also the changes in blood pressure observed 
during orthostasis are comparable for the differ-
ent groups before administration of the drugs 
(Fig. 2). 
After oral administration of midodrine in in-
creasing doses from 2.5 mg up to 15 mg wi th 
an interval of 1 hour we could observe a dose-
dependent significant decrease of heart rate and 
simultaneously a significant increase of systol-
ic blood pressure (Fig. 3). 
Fig. 4.—End-diastolic (EDVI) and stroke volume index (SVI) 
as determined by cardiosonographic measurements before 
(open columns) and after (hatched columns) i.v. injection of 
the various antihypertensive agents. * = p<0.05, ** = p<0.01, 
*** = p< 0.001. The asterisks above the columns represent the 
significance versus the respective control, the asterisks wi-
thin the columns show the significance versus placebo. 
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Fig. 5.—Ejection fraction (EF) and cardiac index (CI) as cal-
culated from end-diastolic and end-systolic silhouettes or 
from stroke volume and heart before (open columns) and af-
ter (hatched columns) i.v. injection of the various antihyper-
tensive drugs. * = p<0.05, ** = p<0.01, ***=p<0.001. The 
asterisks above the columns represent the significance ver-
sus the respective control, the asterisks wi th in the columns 
show the significance versus placebo. 
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Fig. 6.—Plasma noradrenaline concentrations before (0) and during 1, 2, 5 and 10 minutes of passive orthostasis. Before 
treatment = solid lines and black circles, after i.v. injection of the various drug = broken line and open circles. 0 = p<0.05, 
0* = p<0.01, *** = p<0.001). 
Echocardiography.—End-diastolic volume in-
dex was significantly enhanced against control 
and placebo by midodrine. Stroke volume index 
was increased by midodrine and oxilofrine when 
compared to controls and placebo (Fig. 4). We 
did not observe any changes in end-systolic 
volume index (ESVI). 
As a parameter for myocardial contractility the 
ejection fraction was calculated. Oxilofrine but 
not midodrine increased significantly the ejection 
fraction. In addition, cardiac index was enhanced, 
but only after injection of oxilofrine (Fig. 5). 
Plasma catecholamines.—During resting in su-
pine position mean circulating noradrenaline 
(NA) in the volunteers before medication was ap-
proximately 200 pg/ml and was comparable for 
the 5 groups (Fig. 6). After tilting noradrenaline 
concentrations showed a typical pattern, obtain-
ing saturation curves reaching 490-570 pg/ml af-
ter 5 to 10 min. The noradrenaline curves after 
oxilofrine and placebo showed no changes when 
compared to curves before medication. However, 
midodrine decreased N A significantly (p<0.1) 
during the 2nd, 5th and 10th minute of tilting 
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Fig. 7.—Mean concentrations of ST 1059 in plasma of volun-
teers after oral application of 2.5 mg midodrine as hydroch-
loride n = 10. 
(Fig. 6). Circulat ing adrenaline did not change 
under all experimental conditions. 
Pharmacokinetic parameters—The pharmacoki-
netics of midodrine (a-2.5-dimethoxyphenyl-j6-gly-
cinamidoethanol hydrochloride, ST 1085) and its 
main metabolite ST 1059 (a-2.5 dimethoxyphenyl-
ß-aminoethanol hydrochloride) have been inves-
tigated in 12 male healthy volunteers. 2.5 mg 
midodrine hydrochloride were applied intra-
venously, as drinking solution or as tablet (Gu-
tron® ) according to a randomized cross-over de-
sign. Plasma and urine samples collected up to 
24 h after application were analyzed by high-
performance l iquid chromatography with fluo-
rescence detection. The method of high pressure 
l iquid chromatography used had a l imit of sen-
sitivity for detection of 1 and 0.5 ng/ml for mido-
drine and its active metabolite de-glymidodrine 
respectively. 3 The mean maximum concentration 
in plasma for midodrine was ca. 10 ng/ml 20-30 
min after oral administration, for ST 1059 ca 
5 ng/ml after 1 h. Midodrine was eliminated with 
a terminal half-life of 0.5 h. The half-life of ST 
1059 was determined to be 3 h. The mean area 
under the plasma-level vs time curve (AUC) of 
ST 1059 after administration of 2.5 mg mido-
drine i.v. was 28.7 ngxh/ml , and as drinking so-
lution or as tablet 25.7 and 25.6 ngxh /ml , 
respectively (Fig. 7 and Table III). The data of 
10 volunteers could be used for the calculations 
of the bioavailability of ST 1059 by the AUC. As-
suming an interval of equivalence of 0.75-1.25 
because of the relatively small number of volun-
teers, the three formulations are considered to 
be equivalent). 
Discussion 
The aim of the present study was to estimate 
the therapeutic value after acute administration 
of different antihypotensive drugs on the basis 
of determination of cardiac parameters by 2-D-
echocardiography, and assay of circulating 
catecholamines with the help of high pressure 
l iquid chromatography (HPLC). Also blood pres-
sure and heart rate were recorded, especially 
after establishing a dose response curve for oral-
ly administered midodrine. Both parameters can 
be used to estimate pharmacological effects of 
the drugs investigated on the cardiovascular sy-
stem. 
Pharmacodynamic investigations have classi-
fied midodrine as an ^-sympathomimetic drug. 4 
We were able to confirm these findings while 
observing effects, mainly classified as actions on 
post- and presynaptic ^-adrenoceptors. After 
stimulation of postsynaptic a-adrenoceptors 
reflex bradycardia is induced in a dose depen-
dent fashion. The reduced plasma noradrenaline 
concentrations observed during orthostasis in-
dicated probably an action on presynaptic a-
adrenoceptors and/or on baroreflex mechanisms. 
Cl in ica l pharmacology studies on oxilofrine 5 
allow this compound to be classified as a ß-
sympathomimetic drug. /3-sympathomimetic 
agents have a positive inotropic and chronotrop-
ic action on the heart. In accordance with this 
assumption, our results demonstrate an effect 
of oxilofrine on cardiac parameters i.e. increase 
in stroke volume, ejection fraction and cardiac 
index, parameters for myocardial contractility. 6 7 
The data available appear to allow a differen-
tial estimation of the therapeutic value of the 
drugs investigated for pharmacotherapy of or-
thostatic dysregulation. According to the scheme 
of Thulesius, 1976, for differential diagnosis of 
orthostatic dysregulation, the sympathotonic 
reaction (rise in heart rate, fall in systolic blood 
pressure, rise in diastolic blood pressure, reduc-
tion of stroke volume by about 51%) is the most 
frequent, i.e. about 70%, of all forms of postur-
al hypotension. If this type of hypotension is 
present and associated with sequestration of 
blood volume in the leg veins, drugs like di-
hydroergotamine appeared to be most suitable. 
If, however, the blood volume is displaced more 
into the region of the splanchnic or thoracic 
region, treatment with midodrine should be 
recommended. The asympathotonic reaction ac-
cording to Thulesius, 1986 (decreases in systol-
ic and diastolic blood pressure, reduction of 
stroke volume by about 28%, heart rate remains 
unchanged) appeared to be an indication for 
midodrine and oxilofrine. 
Because of their mechanisms of action, these 
drugs are able to increase the sympathetic tone 
by stimulating cardiovascular a- and /3-adren-
oceptors. However, it is not clear whether mido-
drine and its active metabolite stimulates a - or 
c*2-adrenergic receptors. 
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